ERBB2 and liver cancer: Through targeted inhibition of C-MYC and ERBB2 by MBP-1, the positive feedback of PI3K/AKT activation is reversed, thereby forming the mechanism of inhibiting the proliferation and migration of liver cancer cells as a whole.